Patricia Inácio, PhD, science writer —

Abeona Therapeutics is preparing to request U.S. approval of EB-101, a cell therapy candidate for treating recessive dystrophic epidermolysis bullosa (RDEB). The announcement follows a successful pre-biologics license application (BLA) meeting with the U.S. Food and Drug Administration (FDA). “With the constructive feedback from the FDA now in-hand,…

New study findings show how the complement system C5aR2 protein at the surface of neutrophils, a type of immune cell, may contribute to the progression of the rare autoimmune disease epidermolysis bullosa acquisita (EBA). Mice lacking C5aR2 specifically at the surface of neutrophils had lessened inflammation. “Signaling through C5a receptors induces…

Colitis, an inflammation of the large intestine (colon), may develop in rare cases in people with recessive dystrophic epidermolysis bullosa (RDEB), according to a study of one such case. The patient was successfully treated with mesalamine and the steroid budesonide, but more research is needed to “develop evidence-based guidelines…

InMed Pharmaceuticals has completed enrollment for a Phase 2 trial testing INM-755, an investigational cannabinol cream, for people with epidermolysis bullosa (EB). “We look forward to the data read-out in the summer, so we can evaluate our strategic options and next steps,” Eric A. Adams, InMed’s president and CEO,…

Gold weight implants were safely implanted under the eyelids of a woman with recessive dystrophic epidermolysis bullosa (RDEB), according to a recent report. Despite their limited effectiveness in reducing her difficulties completely closing her eyelids — a condition called lagophthalmos — the “safety and tolerability of the gold weight…

A proof-of-concept trial evaluating the effects of Relief Therapeutics’ antimicrobial wound spray RLF-TD011 — formerly known as APR-TD011 — in people with epidermolysis bullosa (EB) has enrolled its first three patients, the company announced. RLF-TD011 is a highly pure form of hypochlorous acid, a chemical with broad-spectrum…

From sharing images and information on social media, to holding fundraisers to spread the word about epidermolysis bullosa (EB), supporters are set to mark National Epidermolysis Bullosa Awareness Week Oct. 25–31. “National Epidermolysis Bullosa Awareness Week … is a time to increase awareness of EB, to promote the need for a…

Squamous cell carcinoma (SCC), a type of skin cancer well known in people with recessive dystrophic epidermolysis bullosa (RDEB), also affects patients with other EB types, according to data from the Dutch EB registry. “The tumours might be discovered only when they are already large because of their indistinct…

Krystal Biotech is seeking U.S. Food and Drug Administration (FDA) approval of Vyjuvek (previously called B-VEC), its topical gene therapy for people with dystrophic epidermolysis bullosa (DEB). The request was made in the form of a biologics license application or BLA — a type of marketing approval —…

Tetra Bio-Pharma’s investigational cannabinoid cream PPP004 (THC-CBD) has been granted orphan drug status by the European Medicines Agency (EMA) to treat epidermolysis bullosa. This follows the orphan drug designation granted to PPP004 by the U.S. Food and Drug Administration (FDA) for the same purpose in April 2020.

Vitamin D supplements are necessary to increase and normalize the vitamin’s levels in the blood of children with recessive dystrophic epidermolysis bullosa (RDEB), according to a single center study in the U.K. Also, the dose should increase with age and can be three times higher than that recommended for…

At-home inhalation of nitrous oxide, a colorless gas commonly used for sedation, may help reduce pain during wound dressings in patients with severe recessive dystrophic epidermolysis bullosa (DEB), a case report shows. For a 28-year-old man in Italy with spontaneous and frequent blisters due to severe DEB, “the beneficial…